secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2026-11-05T02:38:11+00:00
Accession:  0001493152-26-050025
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Bioxytran secures attested Free Sale Certificate for A-SUQAR, targeting UAE and Gulf markets
--------------------------------------------------------------------------------

- A-SUQAR received a government-issued Free Sale Certificate, legalized by the issuing country's Ministry of Foreign Affairs and prepared for attestation for UAE use.
- Certificate confirms A-SUQAR is lawfully manufactured and freely sold as a food and health supplement; Bioxytran plans UAE product registration with its distribution partner.
- Bioxytran will evaluate registration pathways in Saudi Arabia, Kuwait and other GCC markets; launch timing depends on completion of local regulatory requirements.
- A-SUQAR is a pre-meal chewable tablet using polysaccharides to slow intestinal carbohydrate enzymes; it is regulated as a U.S. dietary supplement, not an FDA-approved drug.
- Release cites about 7.5M adults with diabetes across UAE, Saudi Arabia and Kuwait; UAE prevalence 20.7%, Saudi 23.1%, Kuwait 25.6% (IDF 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315226050025/0001493152-26-050025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315226050025/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-050025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer